Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid ends the year on a high note after achieving quarterly targets

The company's ‘million-dollar day’ sale in Japan was successful.
evolis products
Recently signed up with a second U.S. retail partner

Cellmid Limited (ASX:CDY) has achieved key milestones and operational targets for the quarter ended 31 December 2017.

The company’s consumer health subsidiary Advangen sells hair growth products in Australia, Japan and the U.S. and currently generates all of Cellmid’s revenue.

Significantly, Cellmid’s ‘million-dollar day’ sale on 21 December 2017 on the QVC television shopping channel in Japan has been an outstanding success.

Advangen concept store launched in Japan

The store launch in October 2017 was a well-attended public relations event, followed by several articles on Advangen’s technology and products in local publications.

Located in Tokyo’s prestigious Ginza Core shopping centre, the retail store provides hair analysis services in addition to selling products, and is co-promoted with the QVC shopping channel.

Further retail expansion in the U.S.

The company recently signed up with its second U.S. retail partner, Soft Surroundings.  Cellmid had successfully launched its product range on Neiman Marcus online earlier last year.

There will be an online launch initially for Soft Surroundings in a similar path to Neiman Marcus since established retailers require new brands to perform online before they commit to store launches.

The évolis® Professional range launched in Australian salons

The évolis® Professional anti-aging hair care products were launched in Australian salons in November 2017.

The roll-out, primarily through wholesale relationships, will continue in 2018.

Cellmid will engage a small sales force in 2018 to optimise return on investment in this channel, as sales are expected to increase gradually.

Kidney disease studies in Australia progressing well

The ‘in live’ phase of the FSGS (a rare disease that attacks the kidney) studies at the Westmead Institute in Sydney was completed in December 2017.

The tissue and blood data are currently being analysed by Cellmid.

Importantly, there is an early indication that one of the company’s antibodies, not previously tested, is showing efficacy in this model.

READ: Cellmid receives funding from strategic U.S. investor

The company recently received $1 million in the form of a strategic investment from U.S. based investor, Dennis Eck.

Eck is a professional investor with 40 years’ senior management experience in the retail sector including beauty.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

pills
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
cough
Fri
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use